Given that both KAT6A and TGF‐β/SMAD3 are activated in many cancers, including breast cancer, we investigated potential crosstalk between these two intensively studied oncogenic pathways and determined the biological consequence of the KAT6A–SMAD3 signaling in TNBC metastasis. This evidence concerns the gene SMAD3 and breast carcinoma.